Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.
Novo Nordisk is increasingly positioning its GLP-1 medications as lifestyle drugs for 'customers' rather than obesity medicines for 'patients,' marking a significant shift in how the company markets these treatments. The change comes as the company continues developing next-generation weight loss drugs and expands its product pipeline.
Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending Zeydovio (glepaglutide) for marketing authorization in treating short-bowel syndrome. The GLP-2 analog is developed by Zealand Pharma A/S.
Clinical trials for major diseases are experiencing a critical shortage of participants, with only 7% of adult cancer patients in the U.S. enrolling in trials and Alzheimer's treatment studies facing similar global recruitment challenges despite new drug developments.
Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.
Scientists are testing a new approach to fight mesothelioma by developing an experimental drug that kills cancer cells by disabling PRX3, an antioxidant defense mechanism that tumors use to survive oxidative stress. The counterintuitive treatment targets the aggressive asbestos-linked cancer, which currently has few effective treatment options.
AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.
Teva's experimental drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge in a mid-stage study, representing potential progress for a condition with no current drug treatments.
Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.
New study shows that targeting the MDA-9 protein can restrain tumor growth and eliminate therapy resistance in head and neck squamous cell carcinoma, the seventh-most-common cancer type worldwide that is often diagnosed at late stages.
The FDA has approved Takeda's Orzeyful (orexin agonist) for treating narcolepsy type 1 in adults, marking the first approval in a new class of sleep medicines that addresses the full range of narcolepsy symptoms. The approval is expected to reshape the treatment paradigm and launch a closely watched commercial drug race.
Merck beat second-quarter estimates and boosted its 2026 sales forecast after strong demand for newer drugs like Winrevair helped drive revenues higher, though the company cut profit guidance due to deal-related charges.
Scientists have discovered that blocking the Axl receptor may offer a novel approach to promoting bone formation, potentially providing a new treatment avenue for osteoporosis, a common age-related disease affecting millions worldwide.
Gilead Sciences and Merck announced that their experimental once-weekly HIV pill combining islatravir and lenacapavir successfully maintained viral suppression at 48 weeks in two Phase 3 trials (ISLEND-1 and ISLEND-2) involving 1,209 adults with virologically suppressed HIV. The results support regulatory filings for what could become the first once-weekly oral HIV treatment regimen.
The Advanced Research Projects Agency for Health (ARPA-H) has launched a $160 million initiative to fund seven groups over five years to develop custom gene editing drugs, aiming to replicate successes like the Baby KJ case.
The FDA and HHS are implementing sweeping reforms to speed up early-stage drug research in the United States, addressing concerns that pharmaceutical companies have increasingly moved clinical trials to countries like China and Australia. HHS Secretary Robert F. Kennedy Jr. announced the changes aimed at bringing investment back to the U.S.
GSK reported that its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, vastly outpacing current treatments and raising hopes for a finite treatment course as an alternative to lifelong therapy.
Apogee Therapeutics announced a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support late-stage development and potential commercialization of its experimental eczema drug.
The FDA has approved Merck's Idvynso (doravirine/islatravir), a once-daily, two-drug single tablet for treating HIV-1 infection in adults to replace current antiretroviral regimens in virologically suppressed patients.
Researchers who developed GLP-1 obesity medications are now advancing a provocative hypothesis that targeting the GLP-1 hormone may not be necessary for effective weight loss, potentially reshaping the approach to obesity treatment.
